Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Marlous van den Braber"'
Autor:
Sophie A. Dusoswa, Jan Verhoeff, Saskia van Asten, Joyce Lübbers, Marlous van den Braber, Sophie Peters, Sanne Abeln, Matheus H.W. Crommentuijn, Pieter Wesseling, William Peter Vandertop, Jos W. R. Twisk, Thomas Würdinger, David Noske, Yvette van Kooyk, Juan J. Garcia-Vallejo
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundGlioblastomas manipulate the immune system both locally and systemically, yet, glioblastoma-associated changes in peripheral blood immune composition are poorly studied. Age and dexamethasone administration in glioblastoma patients have bee
Externí odkaz:
https://doaj.org/article/60114ef332f047a9a98da36bc515e04a
Autor:
Tom D. Y. Reijnders, Alex R. Schuurman, Jan Verhoeff, Marlous van den Braber, Renée A. Douma, Daniël R. Faber, Alberta G. A. Paul, W. Joost Wiersinga, Anno Saris, Juan J. Garcia Vallejo, Tom van der Poll
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundCommunity-acquired pneumonia (CAP) represents a major health burden worldwide. Dysregulation of the immune response plays an important role in adverse outcomes in patients with CAP.MethodsWe analyzed peripheral blood mononuclear cells by 36
Externí odkaz:
https://doaj.org/article/1c395277784f45d4a2292698566e39b7
Autor:
Simone Brokamp, Annegien Broeks, Christian U. Blank, Petra Herzig, Marlous van den Braber, Daniela S. Thommen, Alfred Zippelius, Marjolein de Bruijn, Joyce Sanders, Ton N. Schumacher, Lisanne M. Roelofsen, Koen J. Hartemink, John B. A. G. Haanen, Kim Monkhorst, Paula Voabil, Sanne H. Hendriks
Publikováno v:
Nature Medicine. 27:1250-1261
Inhibitors of the PD-1–PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-
Autor:
Paula, Voabil, Marjolein, de Bruijn, Lisanne M, Roelofsen, Sanne H, Hendriks, Simone, Brokamp, Marlous, van den Braber, Annegien, Broeks, Joyce, Sanders, Petra, Herzig, Alfred, Zippelius, Christian U, Blank, Koen J, Hartemink, Kim, Monkhorst, John B A G, Haanen, Ton N, Schumacher, Daniela S, Thommen
Publikováno v:
Nature medicine. 27(7)
Inhibitors of the PD-1-PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-1
Autor:
Lindsay G Grijpink-Ongering, Sandra Adriaansz, Pia Kvistborg, Christian U. Blank, John B. A. G. Haanen, Annemarie Bruining, Bart A. van de Wiel, Karolina Sikorska, Daisy Philips, Lorenzo F. Fanchi, Sarah Warren, Ton N. Schumacher, Oscar Krijgsman, Daniel S. Peeper, Annegien Broeks, Harm van Tinteren, Elisa A. Rozeman, H. Mallo, Marlous van den Braber, Loes M. Pronk, Sylvia ter Meulen, Alexander C.J. van Akkooi, Johannes V. Van Thienen, Rachel M. Gittelman
Publikováno v:
Nature Medicine. 24:1655-1661
Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients1,2. In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone and also appears to be mo
Autor:
Christian U. Blank, Akhiad Bercovich, Aviezer Lifshitz, Ido Yofe, Hugo M. Horlings, John B. A. G. Haanen, Hanjie Li, Ton N. Schumacher, Alexander C.J. van Akkooi, Anne van der Leun, Elisa A. Rozeman, Eyal David, Yael Baran, Dikla Gelbard-Solodkin, Marlous van den Braber, Amos Tanay, Ido Amit, Yaniv Lubling
Publikováno v:
Cell
Tumor immune cell compositions play a major role in response to immunotherapy, but the heterogeneity and dynamics of immune infiltrates in human cancer lesions remain poorly characterized. Here, we identify conserved intratumoral CD4 and CD8 T cell b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1583fa0c8771edd3830192ca7506e17
https://europepmc.org/articles/PMC7253294/
https://europepmc.org/articles/PMC7253294/
Autor:
Marlous van den Braber, Arno Velds, Michael R. Stratton, Christian U. Blank, Can Keşmir, Marie Stentoft Svane, Nienke van Rooij, Ton N. Schumacher, Patrick Hwu, Lorenzo F. Fanchi, Mireille Toebes, Daisy Philips, Sam Behjati, Joost H. van den Berg, Marit M. van Buuren, John B. A. G. Haanen, Maarten Slagter, Pia Kvistborg
Publikováno v:
Cancer Immunology Research. 7:B022-B022
Over the past years we have learned that the T-cell-based immune system frequently responds to the neoantigens that arise as a consequence of the accumulated DNA damage causing the malignant transformation. Furthermore, recognition of neoantigens app
Autor:
Kirsten D. Mertz, Alfred Zippelius, Petra Herzig, Daniela S. Thommen, Viktor H. Koelzer, John B. A. G. Haanen, Marjolein de Bruijn, Marlous van den Braber, Ton N. Schumacher, Kim Monkhorst, Paula Voabil, Karlijn Hummelink
Publikováno v:
Cancer Immunology Research. 7:B050-B050
Reinvigoration of tumor-specific T-cells by cancer immunotherapies, in particular PD-1/PD-L1 blocking agents, has greatly improved clinical outcome in multiple cancer types. Nevertheless, durable clinical benefit is currently limited to a small numbe
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1514
The development of peptide loaded major histocompatibility complexes (MHC) conjugated to fluorochromes by Davis and colleagues 20 years ago provided a highly useful tool to identify and characterize antigen-specific T cells. In this chapter we descri
Publikováno v:
Methods in Molecular Biology ISBN: 9781493965465
The development of peptide loaded major histocompatibility complexes (MHC) conjugated to fluorochromes by Davis and colleagues 20 years ago provided a highly useful tool to identify and characterize antigen-specific T cells. In this chapter we descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e98b286d96f792d5fc097f7f7fcf2315
https://doi.org/10.1007/978-1-4939-6548-9_7
https://doi.org/10.1007/978-1-4939-6548-9_7